Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy

Full text
Adams, Volker [1, 2, 3] ; Gussen, Victoria [1] ; Zozulya, Sergey [4] ; Cruz, Andre [5] ; Moriscot, Anselmo [5] ; Linke, Axel [1, 2, 3] ; Labeit, Siegfried [6]
Total Authors: 7
[1] Tech Univ Dresden, Lab Mol & Expt Cardiol, Heart Ctr Dresden, D-1307 Dresden - Germany
[2] Dresden Cardiovasc Res Inst, D-01067 Dresden - Germany
[3] Core Labs GmbH, D-01067 Dresden - Germany
[4] Enamine Bienta Ltd, Dept Drug Res, UA-02000 Kiev - Ukraine
[5] Univ Sao Paulo, Inst Biomed Sci, Dept Anat, BR-05508000 Sao Paulo - Brazil
[6] Heidelberg Univ, Med Fac Mannheim, D-68167 Mannheim - Germany
Total Affiliations: 6
Document type: Journal article
Source: CELLS; v. 9, n. 10 OCT 2020.
Web of Science Citations: 0

Patients with malignant tumors frequently suffer during disease progression from a syndrome referred to as cancer cachexia (CaCax): CaCax includes skeletal muscle atrophy and weakness, loss of bodyweight, and fat tissues. Currently, there are no FDA (Food and Drug Administration) approved treatments available for CaCax. Here, we studied skeletal muscle atrophy and dysfunction in a murine CaCax model by injecting B16F10 melanoma cells into mouse thighs and followed mice during melanoma outgrowth. Skeletal muscles developed progressive weakness as detected by wire hang tests (WHTs) during days 13-23. Individual muscles analyzed at day 24 had atrophy, mitochondrial dysfunction, augmented metabolic reactive oxygen species (ROS) stress, and a catabolically activated ubiquitin proteasome system (UPS), including upregulated MuRF1. Accordingly, we tested as an experimental intervention of recently identified small molecules, Myomed-205 and -946, that inhibit MuRF1 activity and MuRF1/MuRF2 expression. Results indicate that MuRF1 inhibitor fed attenuated induction of MuRF1 in tumor stressed muscles. In addition, the compounds augmented muscle performance in WHTs and attenuated muscle weight loss. Myomed-205 and -946 also rescued citrate synthase and complex-1 activities in tumor-stressed muscles, possibly suggesting that mitochondrial-metabolic and muscle wasting effects in this CaCax model are mechanistically connected. Inhibition of MuRF1 during tumor cachexia may represent a suitable strategy to attenuate skeletal muscle atrophy and dysfunction. (AU)

FAPESP's process: 19/06819-8 - Impact of MuRF-1 and MuRF-2 to skeletal muscle wasting under experimental hyperthyroidism
Grantee:André Cruz de Oliveira
Support type: Scholarships abroad - Research Internship - Doctorate (Direct)
FAPESP's process: 15/04090-0 - Identification and caracterization of mechanisms involved in skeletal muscle mass control and regeneration
Grantee:Anselmo Sigari Moriscot
Support type: Research Projects - Thematic Grants